Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis: Short communication

D. P. Kontoyiannis; V. Ratanatharathorn; J. A. Young; J. Raymond; M. Laverdière; D. W. Denning; T. F. Patterson; D. Facklam; L. Kovanda; L. Arnold; W. Lau; D. Buell; K. A. Marr

doi:10.1111/j.1399-3062.2008.00349.x

Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis: Short communication

D. P. Kontoyiannis, V. Ratanatharathorn, J. A. Young, J. Raymond, M. Laverdière, D. W. Denning, T. F. Patterson, D. Facklam, L. Kovanda, L. Arnold, W. Lau, D. Buell, K. A. Marr

Research output: Contribution to journal › Article › peer-review

Abstract

We describe herein 98 hematopoietic stem cell transplant (HSCT) recipients with invasive aspergillosis (IA) (refractory in 83) who received micafungin either alone (8 patients) or in combination with other licensed antifungal therapies (OLAT) (90 patients). Of the 8 monotherapy patients, 4 were failing OLAT, received de novo micafungin, or were intolerant to prior OLAT (2 patients each). Of the 90 patients treated with combination, 7 had de novo IA and 83 had refractory infection. Most patients (81) had pulmonary IA, 42 (43%) had graft-versus-host disease (GVHD), and 26 (27%) were neutropenic (absolute neutrophil count

Original language	English
Pages (from-to)	89-93
Number of pages	4
Journal	Transplant Infectious Disease
Volume	11
Issue number	1
DOIs	https://doi.org/10.1111/j.1399-3062.2008.00349.x
Publication status	Published - Feb 2009

Keywords

Aspergillus
Combination therapy
Invasive aspergillosis
Micafungin
Stem cell transplantation

Access to Document

10.1111/j.1399-3062.2008.00349.x

Cite this

Kontoyiannis, D. P., Ratanatharathorn, V., Young, J. A., Raymond, J., Laverdière, M., Denning, D. W., Patterson, T. F., Facklam, D., Kovanda, L., Arnold, L., Lau, W., Buell, D., & Marr, K. A. (2009). Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis: Short communication. Transplant Infectious Disease, 11(1), 89-93. https://doi.org/10.1111/j.1399-3062.2008.00349.x

@article{0611ab882e1d4d2cb4bc168aeba90d1f,

title = "Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis: Short communication",

abstract = "We describe herein 98 hematopoietic stem cell transplant (HSCT) recipients with invasive aspergillosis (IA) (refractory in 83) who received micafungin either alone (8 patients) or in combination with other licensed antifungal therapies (OLAT) (90 patients). Of the 8 monotherapy patients, 4 were failing OLAT, received de novo micafungin, or were intolerant to prior OLAT (2 patients each). Of the 90 patients treated with combination, 7 had de novo IA and 83 had refractory infection. Most patients (81) had pulmonary IA, 42 (43%) had graft-versus-host disease (GVHD), and 26 (27%) were neutropenic (absolute neutrophil count",

keywords = "Aspergillus, Combination therapy, Invasive aspergillosis, Micafungin, Stem cell transplantation",

author = "Kontoyiannis, {D. P.} and V. Ratanatharathorn and Young, {J. A.} and J. Raymond and M. Laverdi{\`e}re and Denning, {D. W.} and Patterson, {T. F.} and D. Facklam and L. Kovanda and L. Arnold and W. Lau and D. Buell and Marr, {K. A.}",

year = "2009",

month = feb,

doi = "10.1111/j.1399-3062.2008.00349.x",

language = "English",

volume = "11",

pages = "89--93",

journal = "Transplant Infectious Disease",

issn = "1398-2273",

publisher = "John Wiley & Sons Ltd",

number = "1",

}

Kontoyiannis, DP, Ratanatharathorn, V, Young, JA, Raymond, J, Laverdière, M, Denning, DW, Patterson, TF, Facklam, D, Kovanda, L, Arnold, L, Lau, W, Buell, D & Marr, KA 2009, 'Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis: Short communication', Transplant Infectious Disease, vol. 11, no. 1, pp. 89-93. https://doi.org/10.1111/j.1399-3062.2008.00349.x

Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis: Short communication. / Kontoyiannis, D. P.; Ratanatharathorn, V.; Young, J. A. et al.
In: Transplant Infectious Disease, Vol. 11, No. 1, 02.2009, p. 89-93.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis: Short communication

AU - Kontoyiannis, D. P.

AU - Ratanatharathorn, V.

AU - Young, J. A.

AU - Raymond, J.

AU - Laverdière, M.

AU - Denning, D. W.

AU - Patterson, T. F.

AU - Facklam, D.

AU - Kovanda, L.

AU - Arnold, L.

AU - Lau, W.

AU - Buell, D.

AU - Marr, K. A.

PY - 2009/2

Y1 - 2009/2

N2 - We describe herein 98 hematopoietic stem cell transplant (HSCT) recipients with invasive aspergillosis (IA) (refractory in 83) who received micafungin either alone (8 patients) or in combination with other licensed antifungal therapies (OLAT) (90 patients). Of the 8 monotherapy patients, 4 were failing OLAT, received de novo micafungin, or were intolerant to prior OLAT (2 patients each). Of the 90 patients treated with combination, 7 had de novo IA and 83 had refractory infection. Most patients (81) had pulmonary IA, 42 (43%) had graft-versus-host disease (GVHD), and 26 (27%) were neutropenic (absolute neutrophil count

AB - We describe herein 98 hematopoietic stem cell transplant (HSCT) recipients with invasive aspergillosis (IA) (refractory in 83) who received micafungin either alone (8 patients) or in combination with other licensed antifungal therapies (OLAT) (90 patients). Of the 8 monotherapy patients, 4 were failing OLAT, received de novo micafungin, or were intolerant to prior OLAT (2 patients each). Of the 90 patients treated with combination, 7 had de novo IA and 83 had refractory infection. Most patients (81) had pulmonary IA, 42 (43%) had graft-versus-host disease (GVHD), and 26 (27%) were neutropenic (absolute neutrophil count

KW - Aspergillus

KW - Combination therapy

KW - Invasive aspergillosis

KW - Micafungin

KW - Stem cell transplantation

U2 - 10.1111/j.1399-3062.2008.00349.x

DO - 10.1111/j.1399-3062.2008.00349.x

M3 - Article

SN - 1398-2273

VL - 11

SP - 89

EP - 93

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

IS - 1

ER -

Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis: Short communication

Abstract

Keywords

Access to Document

Fingerprint

Cite this